Human IgM and IgG Responses to an Inactivated SARS-CoV-2 Vaccine

Abstract

Objective

The ongoing COVID-19 pandemic warrants accelerated efforts to test vaccine candidates. To explore the influencing factors on vaccine-induced effects, antibody responses to an inactivated SARS-CoV-2 vaccine in healthy individuals who were not previously infected by COVID-19 were assessed.

Methods

All subjects aged 18–60 years who did not have SARS-CoV-2 infection at the time of screening from June 19, 2021, to July 02, 2021, were approached for inclusion. All participants received two doses of inactivated SARS-CoV-2 vaccine. Serum IgM and IgG antibodies were detected using a commercial kit after the second dose of vaccination. A positive result was defined as 10 AU/mL or more and a negative result as less than 10 AU/mL. This retrospective study included 97 infection-naïve individuals (mean age 35.6 years; 37.1% male, 62.9% female).

Results

The seropositive rates of IgM and IgG antibody responses elicited after the second dose of inactivated SARS-CoV-2 vaccine were 3.1% and 74.2%, respectively. IgG antibody levels were significantly higher than IgM levels (P<0.0001). Sex had no effect on IgM and IgG antibody response after the second dose. The mean anti-IgG level in older persons (⩾42 years) was significantly lower than that of younger recipients. There was a significantly lower antibody level at > 42 days compared to that at 0–20 days (P<0.05) and 21–31 days (P<0.05) after the second dose.

Conclusion

IgG antibody response could be induced by inactivated SARS-CoV-2 vaccine in healthy individuals (>18 years), which can be influenced by age and detection time after the second dose of vaccination.

Keywords

COVID-19 / inactivated SARS-CoV-2 vaccine / IgM and IgG antibody responses

References

[1] ChanJFW, YuanS, KokKH, et al.. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet, 2020, 395(10223): 514-523

[2] ChenN, ZhouM, DongX, et al.. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet, 2020, 395(10223): 507-513

[3] LiQ, GuanX, WuP, et al.. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus Infected Pneumonia. N Engl J Med, 2020, 382(13): 1199-1207

[4] WangC, HorbyPW, HaydenFG, et al.. A novel coronavirus outbreak of global health concern. Lancet, 2020, 395(10223): 470-473

[5] ZhuN, ZhangD, WangW, et al.. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med, 2020, 382(8): 727-733

[6] Weekly epidemiological update on COVID-19 - 24 August 2021. Available from: https://www.who.int/publications/m/item/weekly-epidemiological-update-on COVID-19—24-august-2021. [Accessed August 29, 2021].

[7] TezerH, Bedir DemirdağT. Novel Coronavirus disease (COVID-19) in children. Turk J Med Sci, 2020, 50(SI-1): 592-603

[8] CruzMP, SantosE, Velázquez CervantesMA, et al.. COVID-19, a worldwide public health emergency. Rev Clin Esp (Barc), 2021, 221(1): 55-61

[9] XiaS, DuanK, ZhangY, et al.. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials. JAMA, 2020, 324(10): 951-960

[10] FolegattiPM, EwerKJ, AleyPK, et al.. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet, 2020, 396(10249): 467-478

[11] WangF, KreamRM, StefanoGB. An Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development. Med Sci Monit, 2020, 26: e924700

[12] ZhuFC, GuanXH, LiYH, et al.. Immunogenicity and safety of a recombinant adenovirus type 5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double blind, placebo-controlled, phase 2 trial. Lancet, 2020, 396(10249): 479-488

[13] COVID-19 vaccine tracker and landscape. Available from:https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.[Accessed August 31, 2021].

[14] BadenLR, El SahlyHM, EssinkB, et al.. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med, 2021, 384(5): 403-416

[15] PolackFP, ThomasSJ, KitchinN, et al.. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med, 2020, 383(27): 2603-2615

[16] VoyseyM, ClemensSAC, MadhiSA, et al.. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in 8 Brazil, South Africa, and the UK. Lancet, 2021, 397(10269): 99-111

[17] XiaS, ZhangY, WangY, et al.. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis, 2021, 21(1): 39-51

[18] CallawayE. Mix-and-match COVID vaccines trigger potent immune response. Nature, 2021, 593(7860): 491-491

[19] HouH, WangT, ZhangB, et al.. Detection of IgM and IgG antibodies in patients with coronavirus disease 2019. Clin Transl Immunology, 2020, 9(5): e01136

[20] DorofteiB, CiobicaA, IlieO-D, et al.. Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines. Diagnostics (Basel), 2021, 11(4): 579

[21] SalvagnoGL, HenryBM, PiazzaG di, et al.. Anti-SARS-CoV-2 Receptor-Binding Domain Total Antibodies Response in Seropositive and Seronegative Healthcare Workers Undergoing COVID2019 mRNA BNT162b2 Vaccination. Diagnostics (Basel), 2021, 11(5): 832

[22] TerposE, TrougakosIP, ApostolakouF, et al.. Age-dependent and gender-dependent antibody responses against SARS-CoV-2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccine. Am J Hematol, 2021, 96(7): E257-E259

[23] Abu JabalK, Ben-AmramH, BeirutiK, et al.. Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021. Euro Surveill, 2021, 26(6): 2100096

[24] GrupperA, SharonN, FinnT, et al.. Humoral Response to the Pfizer BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis. Clin J Am Soc Nephrol, 2021, 16(7): 103701042

[25] Ward H, Cooke G, Whitaker M, et al. REACT-2 Round 5: increasing prevalence of SARS-CoV-2 antibodies demonstrate impact of the second wave and of vaccine roll-out in England. Available from: https://www.medrxiv.org/content/10.1101/2021.02.26.21252512v1.

[26] JaraA, UndurragaEA, GonzálezC, et al.. Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile. N Engl J Med, 2021, 385(10): 875-884

[27] MurinCD, WilsonIA, WardAB. Antibody responses to viral infections: a structural perspective across three different enveloped viruses. Nat Microbiol, 2019, 4(5): 734-747

[28] RacineR, WinslowGM. IgM in microbial infections: taken for granted?. Immunol Lett, 2009, 125(2): 79-85

[29] JalkanenP, KolehmainenP, HäkkinenHK, et al.. COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants. Nat Commun, 2021, 12(1): 3991

[30] Röltgen K, Nielsen SCA, Arunachalam PS, et al. mRNA vaccination compared to infection elicits an IgG-predominant response with greater SARS-CoV-2 specificity and similar decrease in variant spike recognition. medRxiv. 2021:2021.04.05.21254952

[31] BadenLR, El SahlyHM, EssinkB, et al.. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med, 2021, 384(5): 403-416

[32] OmerSB, YildirimI, FormanHP. Herd Immunity and Implications for SARS-CoV-2 Control. JAMA, 2020, 324(20): 2095-2096

[33] Immunization coverage. Available from: https://www.who.int/news16room/fact-sheets/detail/immunization-coverage. [Accessed October 2, 2021].

[34] MalloryML, LindesmithLC, BaricRS. Vaccination-induced herd immunity: Successes and challenges. J Allergy Clin Immunol, 2018, 142(1): 64-66

[35] KwokKO, LaiF, WeiWI, et al.. Herd immunity-estimating the level required to halt the COVID-19 epidemics in affected countries. J Infect, 2020, 80(6): e32-e33

[36] DörschugA, FrickmannH, SchwanbeckJ, et al.. Comparative Assessment of Sera from Individuals after S-Gene RNA-Based SARS-CoV-2 Vaccination with Spike-Protein-Based and Nucleocapsid Based Serological Assays. Diagnostics (Basel), 2021, 11(3): 426

[37] RanzaniOT, HitchingsMDT, DorionM, et al.. Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study. BMJ, 2021, 374: n2015

[38] Müller L, Andrée M, Moskorz W, et al. Age-dependent immune response to the Biontech/Pfizer BNT162b2 COVID-19 vaccination. Clin Infect Dis, 2021:ciab381

[39] QuastI, TarlintonD. B cell memory: understanding COVID-19. Immunity, 2021, 54(2): 205-210

[40] KhodadadiL, ChengQ, RadbruchA, et al.. The Maintenance of Memory Plasma Cells. Front Immunol, 2019, 10: 721

[41] BaumgarthN, Nikolich-ŽugichJ, LeeFEH, et al.. Antibody Responses to SARS-CoV33 2: Let’s Stick to Known Knowns. J Immunol, 2020, 205(9): 2342-2350

[42] TurnerJS, O’HalloranJA, KalaidinaE, et al.. SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. Nature, 2021, 596(7870): 109-113